Injective Gets a $100M Treasury and Binance Staking Push

Injective (INJ), the DeFi focused layer-1 blockchain, is drawing fresh institutional and retail attention in mid-2026 after two separate developments landed close together. Pineapple Financial has been building a roughly $100 million Injective Digital Asset Treasury, an INJ focused corporate reserve, while Binance.US rolled out weekly staking for INJ to users in the United States. Together, the moves have put a spotlight on how listed companies and regulated exchanges are treating Injective and its native token.

What Pineapple Financial announced

Pineapple Financial, a publicly traded company, set out to establish a digital asset treasury centered on INJ rather than the usual Bitcoin or Ether reserves. According to company press releases distributed through Nasdaq, Newsfile and other outlets, the strategy is built around a target of around $100 million and positions Pineapple as the first publicly traded INJ holder worldwide. The program is supported by a roster of digital asset firms, with participants including FalconX, Kraken, Blockchain.com, Canary Capital, Monarq and the Injective Foundation named across the announcements.

The treasury was funded through a private placement and has been deployed in stages. Per the filings and follow up updates, Pineapple completed open market purchases of INJ and continued to add to the position over time. The company has also pointed to staking the holdings as a way to generate yield, working with institutional infrastructure partners that handle validator selection, delegation and treasury execution.

Why an INJ treasury stands out

Corporate digital asset treasuries became a familiar theme over the past few years, but most of them concentrated on Bitcoin. A reserve built around an altcoin like INJ is less common, which is part of why the Pineapple plan attracted coverage. It signals that some companies are willing to look beyond the largest assets and toward layer-1 networks that offer staking rewards and on-chain utility.

Injective is designed for financial applications, with order book based trading and support for derivatives and tokenized assets built into the chain. For a treasury strategy, the appeal is twofold: exposure to the token itself, plus the ability to stake INJ and earn protocol rewards while supporting network security. The exact yield depends on staking conditions and changes over time, so figures cited by various sources differ, and Pineapple has framed its targets in its own updates rather than guaranteeing a fixed return.

• The treasury concentrates on a single layer-1 token rather than a basket.
• Staking rewards are part of the thesis, not just price exposure.
• Institutional partners handle custody, validation and execution.
• The structure ties a listed equity to on-chain Injective activity.

Binance.US opens weekly INJ staking

The second tailwind came from the exchange side. Binance.US launched INJ staking for users in the United States, a move reported around May 29, 2026 by outlets including Invezz, The Coin Republic and CoinMarketCap. The product lets US based holders stake INJ, earn staking rewards and support the network, with the offering described as paying out on a weekly basis while keeping unstaking flexible.

Access matters here. Regulated US platforms have historically been cautious about which tokens they allow for staking, so adding INJ widens the pool of users who can earn rewards without leaving a familiar, compliant venue. For many retail holders, an exchange based staking option is simpler than self custody and direct delegation to a validator.

Market context and price reaction

The staking news coincided with a sharp move in INJ. According to The Coin Republic, the token gained roughly 39% over a seven day stretch and about 8% in a single day, pushing back toward the $6 area and what the outlet called its highest level since November 2025. Reports from Invezz and CoinMarketCap also tied the rally to the Binance.US staking launch, with double digit weekly gains noted across coverage.

One supply dynamic kept coming up in the reporting: a large share of INJ is already locked in staking. Around 58% of the token supply was described as staked, and analysts quoted in the coverage suggested that more regulated staking access could pull additional tokens out of liquid circulation. Less freely traded supply can affect price behavior, though that is a market dynamic rather than a guarantee, and short term moves driven by a single catalyst can fade.

Traders who want to follow the action directly can track INJ markets, liquidity and on-chain activity on DEXTools, which is useful for watching how trading volume and pairs respond when news like this hits. On-chain dashboards help separate sustained interest from a quick, headline driven spike.

What it means

Taken together, the two stories point in the same direction: more avenues for both institutions and everyday users to hold and stake INJ. A listed company committing to an INJ treasury is a vote of confidence in the token as a reserve asset, while a US exchange enabling weekly staking lowers the barrier for retail participation. Neither development changes Injective's underlying technology, but both expand the ways capital can flow into the network.

It is worth keeping the scale in perspective. A treasury target of around $100 million is meaningful for a single company, yet modest next to the broader INJ market, and exchange staking is now common across many large tokens. The notable part is the combination: corporate accumulation and regulated retail access arriving in the same window, which is what amplified the attention on Injective.

What is next

Watch for follow up disclosures from Pineapple on how its treasury is deployed and staked, since the company has issued periodic updates on the size and composition of its INJ holdings. On the exchange side, the key question is adoption: how many US users opt into Binance.US staking and whether other regulated platforms follow with similar INJ products. Protocol level changes on Injective, including any updates to its token economics, will also shape how attractive staking remains.

For now, the takeaway is that Injective is benefiting from two distinct sources of demand at once. Whether that turns into durable growth or a temporary boost will depend on execution, market conditions and continued interest from both sides of the table. As always, this is information, not financial advice, and readers should do their own research before acting on any of it.